Procedural and Clinical Outcomes after Use of the Glycoprotein IIb/IIIa inhibitor Abciximab for Saphenous Vein Graft Interventions

Percutaneous coronary intervention (PCI) of saphenous vein grafts (SVG) poses a high-risk for distal coronary thromboembolic events. Glycoprotein IIb/IIIa inhibitors are frequently used in hope of reducing the impact of this, although the safety and efficacy of these drugs to improve outcomes in this setting are understudied.

Source: Cardiovascular Revascularization Medicine - October 30, 2015 Category: Cardiology Authors: Ralf E. Harskamp, Niels Hoedemaker, L. Kristin Newby, Pier Woudstra, Maik J. Grundeken, Marcel A. Beijk, Jan J. Piek, Jan G. Tijssen, Rajendra H. Mehta, Robbert J. de Winter Source Type: research